Hisamitsu buys into Japanese transdermal firm
This article was originally published in Scrip
The transdermal specialist Hisamitsu has acquired a 15% holding in a Japanese firm that it is already collaborating with for the co-marketing of one of its main products.
You may also be interested in...
Positive clinical results in Parkinson’s pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.